TU Dresden

Preparations for the 1st Dresdner Aktionstag Demenz are in full swing
On May 10, 2017 the CRTD together with the Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Universitätsklinikum Carl Gustav Carus Dresden and Volkshochschule Dresden e.V. will present a... [read more]
© Martin Kaßner / CRTD
UniStem Day 2017 with talks, tours and various activities successfully performed
Europe-wide UniStem Day on March 17, 2017 with Dresden high school students was a great success. [read more]
Dr. Volker Busskamp was awarded the Paul Ehrlich- and Ludwig Darmstaedter Prize for Young Researchers 2017
On March 14, 2017 – CRTD research group leader Dr. Volker Busskamp was awarded the Paul Ehrlich- and Ludwig Darmstaedter Prize for Young Researchers 2017 in Frankfurt.  [read more]
© Uwe Dettmar
T cells in babies give clues to who will develop type 1 diabetes
The research group of Prof. Ezio Bonifacio introduces a new understanding of cellular mechanisms occurring in babies having a high risk of developing type 1 diabetes.  [read more]
Recently discovered special cells in babies help to understand why some children develop type 1 diabetes whereas others do not © Stephan Wiegand

At the DFG-Center for Regenerative Therapies Dresden (CRTD), our mission is to understand the biology of stem cells and physiological and pathological tissue and organ repair in order to develop new treatments for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, haematological diseases, such as leukemia, metabolic diseases, such as diabetes, and bone diseases. Our scientists are encouraged to think outside the box and to explore untapped areas of knowledge in the regenerative potential of the human body, and to apply this knowledge to prevent or reverse disease processes.

To achieve our aims, we strongly support interdisciplinary research, with eighteen core groups in a network of 87 principal investigators from diverse research institutes on the Dresden campus, with expertise in everything from the biology of cells and tissues to biomaterials to nanoengineering. CRTD has become a major driving force on campus and is ready to meet the challenges of moving new interventional strategies from bench to bedside.